NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free QNCX Stock Alerts $1.06 +0.03 (+2.91%) (As of 04/26/2024 08:53 PM ET) Add Compare Share Share Today's Range$0.98▼$1.0850-Day Range$0.94▼$1.3552-Week Range$0.84▼$1.74Volume120,800 shsAverage Volume77,298 shsMarket Capitalization$45.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Quince Therapeutics alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Quince Therapeutics Stock (NASDAQ:QNCX)Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Read More QNCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNCX Stock News HeadlinesApril 28, 2024 | americanbankingnews.comHumacyte (NASDAQ:HUMA) versus Quince Therapeutics (NASDAQ:QNCX) Head-To-Head SurveyApril 25, 2024 | finance.yahoo.comQuince Therapeutics, Inc. (QNCX)April 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 2, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023April 1, 2024 | finance.yahoo.comQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsFebruary 22, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | businesswire.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 15, 2024 | finance.yahoo.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 15, 2024 | businesswire.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsJanuary 4, 2024 | finance.yahoo.comQuince Therapeutics to Participate at Investor Events in January 2024November 11, 2023 | morningstar.comQuince Therapeutics Inc QNCXOctober 27, 2023 | benzinga.comChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 SharesOctober 25, 2023 | benzinga.comQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock OptionsOctober 23, 2023 | finance.yahoo.comQuince Therapeutics Completes Acquisition of EryDel S.p.A.September 28, 2023 | msn.comFDA lifts partial clinical hold on EryDel lead product EryDexSeptember 28, 2023 | finance.yahoo.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 7, 2023 | benzinga.comQuince Therapeutics President Awarded $692K Worth of Stock OptionsSeptember 6, 2023 | bizjournals.comDaily Digest: Currys aim to raise $50M for Oakland schools; Sotheby's opens new officeSeptember 6, 2023 | finance.yahoo.comQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentAugust 18, 2023 | benzinga.com325K Reasons To Be Bullish On Quince Therapeutics StockAugust 14, 2023 | benzinga.comQuince Therapeutics And 2 Other Stocks Under $3 Insiders Are BuyingAugust 11, 2023 | finance.yahoo.comQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023July 26, 2023 | finanznachrichten.deQUINCE THERAPEUTICS INCJuly 24, 2023 | benzinga.comWhat's Going On With Quince Therapeutics Stock TodayJuly 24, 2023 | finance.yahoo.comQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityJuly 13, 2023 | msn.comEcho Lake bumps up bid to buy Quince Therapeutics to $1.80See More Headlines Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:QNCX CUSIPN/A CIK1662774 Webwww.quincetx.com Phone(650) 910-5717FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.36% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.16 Current Ratio8.09 Quick Ratio8.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.98 per share Price / Book0.54Miscellaneous Outstanding Shares43,220,000Free Float34,140,000Market Cap$45.81 million OptionableOptionable Beta1.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Dirk Thye M.D. (Age 54)CEO & Director Comp: $681.36kMr. Brendan Hannah M.B.A. (Age 38)Principal Financial Officer, Principal Accounting Officer, Chief Business Officer & COO Comp: $504.34kDr. Charles S. Ryan J.D. (Age 60)Ph.D., President Dr. Guenter R. Janhofer M.D.Ph.D., Chief Scientific OfficerMs. Stacy RoughanVice President of Corporate Communications & Investor RelationsMs. Mary Ellen SillivosVice President of Human ResourcesDr. Stewart A. Low Ph.D.Head of DiscoveryMore ExecutivesKey CompetitorsCidara TherapeuticsNASDAQ:CDTXDyadic InternationalNASDAQ:DYAINKGen BiotechNYSE:NKGNAVROBIONASDAQ:AVROSAB BiotherapeuticsNASDAQ:SABSView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%David LamondBought 22,627 shares on 12/14/2023Total: $23,532.08 ($1.04/share)David LamondBought 22,327 shares on 12/12/2023Total: $22,773.54 ($1.02/share)David LamondBought 19,123 shares on 12/7/2023Total: $19,314.23 ($1.01/share)David LamondBought 19,123 shares on 12/5/2023Total: $19,314.23 ($1.01/share)View All Insider TransactionsView All Institutional Transactions QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed in 2024? Quince Therapeutics' stock was trading at $1.05 at the start of the year. Since then, QNCX shares have increased by 1.0% and is now trading at $1.06. View the best growth stocks for 2024 here. When is Quince Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our QNCX earnings forecast. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) issued its quarterly earnings data on Monday, April, 1st. The company reported ($0.21) earnings per share for the quarter. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QNCX) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
